Led by Neon, the oversubscribed-round accelerates expansion into AI precision digestive healthcare and autoimmune health, driven by rapid scaling across national health plans, jumbo employers and major benefit platforms.

在Neon的领导下，这轮超额认购的融资加速了公司在AI精准消化健康及自身免疫健康领域的扩张，这一增长得益于其在全国性健康计划、大型企业雇主以及主要福利平台上的快速规模化布局。

BOSTON

波士顿

,

，

Sept. 16, 2026

2026年9月16日

/PRNewswire/ --

/美通社/ --

Ayble Health

艾布尔健康

, the nation's leading AI-enabled virtual multidisciplinary GI clinic, today announced the close of a $16 million oversubscribed Series A round led by

，全国领先的AI赋能虚拟多学科胃肠病诊所，今日宣布完成一轮超额认购的1600万美元A轮融资，由

Neon

霓虹

, with participation from Unum Ventures, Upfront Ventures, M13, Cleveland Clinic Ventures, DigiTx, Accomplice and several individual strategic investors. The round brings Ayble's total capital raised to over $27 million.

，并有 Unum Ventures、Upfront Ventures、M13、克利夫兰诊所风险投资部门（Cleveland Clinic Ventures）、DigiTx、Accomplice 以及多位个人战略投资者参与。本轮融资使 Ayble 的累计融资总额超过 2,700 万美元。

Undertreated, Underserved, and Enormously Costly

治疗不足、服务欠缺且成本高昂

Digestive and autoimmune conditions are among the most common, costly, and under-addressed chronic diseases in the country. GI conditions alone affect more than

消化系统和自身免疫性疾病是该国最常见、治疗成本最高且最未被充分重视的慢性疾病。仅胃肠道疾病就影响了超过

70 million Americans

7000万美国人

and drive $136 billion in annual U.S. healthcare spending, more than the total cost of diabetes or heart disease, while nearly 70% of U.S. counties lack a single practicing gastroenterologist. The two categories are also clinically intertwined: a

并导致美国每年医疗保健支出增加1,360亿美元，超过糖尿病或心脏病的总成本，而美国近70%的县缺乏一名执业胃肠病学家。这两类疾病在临床上也相互交织：a

2025 study spanning

2025年研究涵盖

more than 141 million patients found inflammatory bowel disease (IBD) associated with 24 distinct autoimmune comorbidities, underscoring the need for a care model built to treat patients across both conditions.

超过1.41亿名炎症性肠病（IBD）患者被发现伴有24种不同的自身免疫性共病，这凸显了建立一种能够同时治疗这两种疾病的照护模式的必要性。

Meeting this dual burden requires a care model that can adapt to each patient's overlapping conditions rather than treating them in isolation. This new capital will be used to advance Ayble's proprietary AI+clinician precision care model, deepening data-driven personalization for patient engagement, enrollment, and care delivery.

应对这种双重负担需要一种能够适应每位患者重叠病情的护理模式，而非孤立地对待各种病症。这笔新资金将用于推进 Ayble 专有的“AI+临床医生”精准护理模式，深化数据驱动的个性化服务，以提升患者参与度、入组率及护理交付效果。

Additionally, the company will leverage its proven multidisciplinary model and data infrastructure to expand beyond its core gastrointestinal (GI) footprint into adjacent complex therapeutic areas, starting with autoimmune conditions..

此外，公司将利用其经证实的多学科模式和数据基础设施，从核心的胃肠道（GI）领域扩展到相邻的复杂治疗领域，首先从自身免疫性疾病开始。

Unprecedented Scale and Enterprise Access

前所未有的规模与企业级访问权限

That expansion is underpinned by several years of rapid commercial growth, positioning Ayble to bring its model to an even broader population. Ayble is now in-network with most commercial health plans and covers 80+ million Americans through payer, employer, and health system partnerships. Recently, Ayble was nominated for the .

这一扩张得益于数年的快速商业增长，使Ayble能够将其模式推广至更广泛的人群。Ayble目前已纳入大多数商业健康计划的网络，并通过与支付方、雇主及医疗系统的合作，覆盖超过8,000万美国人。近期，Ayble获得提名。

Galien Prize

加伦奖

, widely regarded as the highest honor in biomedical innovation, often described as the Nobel Prize equivalent for life sciences, biotechnology and digital health.

，被广泛视为生物医学创新领域的最高荣誉，常被称为生命科学、生物技术和数字健康领域的“诺贝尔奖”。

'I built Ayble because I'm an Inflammatory Bowel Disease patient,' said Sam Jactel, Founder and CEO of Ayble Health. 'I've lived through the diagnostic delays, the care gaps, and the overall frustration of a system that isn't designed for patients who need ongoing, coordinated care. Many patients are also managing autoimmune conditions, and too often, no one is treating the whole picture.

“我创立Ayble是因为我是一名炎症性肠病患者，”Ayble Health的创始人兼首席执行官Sam Jactel表示。“我曾亲身经历过诊断延误、护理缺口，以及整个医疗系统未能满足需要持续、协调照护的患者需求所带来的种种挫折。许多患者还同时患有自身免疫性疾病，但往往没有人从整体角度进行综合治疗。”

This funding lets us close that gap: deepening our AI precision care capabilities and extending our multidisciplinary model into autoimmune, so patients get one team built for how these conditions actually show up in their lives. The growth we've seen and the partnerships we've built with leading employers, payers and providers demonstrates the need for our work is massive.'.

这笔资金使我们能够弥补这一差距：深化我们的AI精准医疗能力，并将我们的多学科模式扩展至自身免疫性疾病领域，从而为患者提供一个根据其疾病在实际生活中的表现而打造的专业团队。我们所见证的增长以及我们与领先雇主、支付方和提供方建立的合作伙伴关系，表明市场对我们工作的需求极为巨大。

A System Under Strain

不堪重负的系统

Beyond the direct cost of care, digestive disease is driving broader strain on the healthcare system. GI conditions are the leading cause of treat-and-release emergency room visits, and patients face average wait times of

除了直接的医疗护理成本外，消化系统疾病正给医疗保健系统带来更广泛的压力。胃肠道疾病是导致“治疗后即释放”急诊就诊的首要原因，患者面临的平均等待时间为

40 days

40天

for an in-person specialty visit. For employers and payers, the burden is escalating: GI conditions consistently rank as a top-five driver of medical claims and represent one of the fastest-growing cost centers across commercially insured populations; closely following digestive costs are those linked to autoimmune conditions..

针对线下专科就诊。对雇主和支付方而言，负担日益加重：胃肠道疾病始终是医疗理赔的前五大驱动因素之一，也是商业保险人群中成本增长最快的领域之一；紧随其后的是与自身免疫性疾病相关的费用。

'I've been tracking the GI space closely for years, and what Ayble has built is different,' said Kimmy Scotti, Founding and Managing Partner at Neon, who previously co-founded 8VC, 'Having invested early in top digital health companies, I've seen what it takes to build a category-defining company in healthcare.

“多年来，我一直密切关注胃肠道（GI）领域，而Ayble所打造的成果与众不同，”Neon的创始兼管理合伙人Kimmy Scotti表示。她曾联合创立8VC。“通过早期投资顶尖的数字健康公司，我深知在医疗健康领域打造一家定义品类标杆的企业所需具备的条件。”

Ayble has spent years building the clinical evidence before they scaled the business. That earns trust from the full ecosystem: health systems, payers, and most importantly, patients, and it's what makes a durable market leader.'.

Ayble在扩大业务规模之前，花了数年时间积累临床证据。这赢得了整个生态系统的信任：包括医疗系统、支付方，以及最重要的患者群体，这也正是其成为持久市场领导者的关键所在。

Setting the Gold Standard in Multidisciplinary Digestive Healthcare

树立多学科消化健康护理的黄金标准

Ayble directly addresses this crisis by combining specialized clinical expertise with advanced technology. Its integrated, multidisciplinary care model pairs GI-trained providers, registered dietitians, behavioral health specialists, clinical pharmacists, health coaches, and care coordinators with proprietary technology powered by one of the largest GI datasets in the world.

Ayble通过将专业的临床专业知识与先进技术相结合，直接应对这一危机。其整合型多学科护理模式将接受过胃肠病学培训的提供者、注册营养师、行为健康专家、临床药师、健康教练和护理协调员与专有技术相配对，该技术由全球最大的胃肠病学数据集之一提供支持。

An .

一个。

independent analysis from the Peterson Health Technology Institute

彼得森健康技术研究所的独立分析

recognized Ayble's clinical team as the broadest in the GI category.

认可 Ayble 的临床团队为胃肠道（GI）领域中最广泛的团队。

Ayble's care model is grounded in unmatched clinical rigor, with +16 peer-reviewed clinical studies across every major GI population – more than any other virtual digestive health company. Conducted in collaboration with leading academic researchers at the Rome Foundation, University of Washington, Cleveland Clinic, Northwestern Medicine and Sutter Health, this research validates Ayble's ability to drive transformative clinical outcomes at scale.

Ayble 的护理模式建立在无与伦比的临床严谨性之上，涵盖所有主要胃肠道人群，拥有超过 16 项经同行评审的临床研究——数量超过任何其他虚拟消化健康公司。这项研究与罗马基金会、华盛顿大学、克利夫兰诊所、西北医学和萨特医疗的顶尖学术研究人员合作开展，验证了 Ayble 在大规模范围内推动变革性临床成果的能力。

Across its book of business, Ayble achieves an average 47% improvement in GI symptoms for patients, typically within four weeks and sustained for at least a year. For enterprise partners, this clinically-validated care translates directly to reduced high-cost utilization, delivering a minimum 3:1 return on investment..

在其业务覆盖范围内，Ayble 帮助患者平均改善 47% 的胃肠道（GI）症状，通常在四周内见效，并至少维持一年。对于企业合作伙伴而言，这种经临床验证的护理方案可直接降低高成本医疗资源的使用，带来最低 3:1 的投资回报率。

With this funding, Ayble will extend its clinically validated model, built on years of rigorous evidence, to millions more patients managing GI and autoimmune disease, at a moment when access to specialty care has never been harder to find. To learn more, please visit

凭借这笔资金，Ayble 将其基于多年严谨证据构建并经临床验证的模型，扩展至更多数百万管理胃肠道和自身免疫性疾病的患者，这在专科医疗资源前所未有的稀缺时刻显得尤为重要。欲了解更多信息，请访问

www.ayblehealth.com

www.ayblehealth.com

.

。

About Neon:

关于 Neon：

Neon is an early-growth stage venture capital firm investing best-in-class entrepreneurs innovating at the intersection of healthcare and consumer to envision a better future and change outcomes for American patients.

Neon 是一家处于早期成长阶段的风险投资公司，专注于投资在医疗保健与消费领域交叉地带进行创新的顶尖创业者，旨在展望更美好的未来并改善美国患者的健康结果。

About Ayble Health

关于 Ayble Health

Ayble Health is the country's most clinically-validated virtual clinic for chronic digestive and autoimmune conditions. Nominated for the 2026 Galien Prize and named to TIME's 2024 Best Solutions for GI list, Ayble's award-winning care model offers unlimited access to a specialized, multidisciplinary care team, a suite of AI-powered precision tools, and curated wellness support, all designed to drive sustainable symptom improvement for patients across the entire acuity spectrum.

Ayble Health 是全国在慢性消化系统和自身免疫性疾病领域临床验证最充分的虚拟诊所。获提名2026年盖伦奖，并入选《时代》周刊2024年最佳胃肠道解决方案榜单，Ayble 屡获殊荣的护理模式提供对专业化多学科护理团队的无限访问权限、一套人工智能驱动的精准工具以及精心策划的健康支持，旨在为各种病情严重程度的患者推动可持续的症状改善。

Ayble is backed by 16 peer-reviewed publications and independently evaluated by the Peterson Health Technology Institute and the Validation Institute. Ayble works with leading employers, health insurance plans, health systems, and community GI practices to scale access to multidisciplinary care, reduce healthcare costs, and improve the lives of millions of Americans with chronic digestive diseases.

Ayble 拥有 16 篇经同行评审的出版物作为支持，并接受了彼得森健康技术研究所（Peterson Health Technology Institute）和验证研究所（Validation Institute）的独立评估。Ayble 与领先的雇主、健康保险计划、医疗系统以及社区胃肠病诊所合作，扩大多学科护理的可及性，降低医疗成本，并改善数百万患有慢性消化系统疾病的美国人的生活。

Visit .

访问。

www.ayblehealth.com

www.ayblehealth.com

to learn more.

了解更多。

CONTACT:

联系方式：

[email protected]

[email protected]

SOURCE Ayble Health, Inc.

来源：Ayble Health, Inc.

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，借助

Request a Demo

申请演示